Report Overview

The Global Cardiovascular Drugs market was pegged at US$ 50.3 billion in 2021 and is expected to witness a CAGR of 3.60 % during the forecast period. 

Market Fundamentals 

Cardiovascular drugs are compounds used to treat various cardiac conditions (including congestive heart failure, angina, or arrhythmia) or vascular illnesses such as hypertension. There are three basic ways that cardiovascular drugs impact the working of heart. They may have an impact on the heart's ability to contract forcefully (inotropic effects), the frequency or intensity of heartbeats (chronotropic effects), or the regularity of heartbeats (rhythmic effects). The drugs are effective in conditions of heart failure (insufficient heart output compared to the needs of the rest of the body), hypertension (high blood pressure), angina pectoris (chest pain brought on by insufficient blood flow through the coronary arteries to the heart muscle), and arrhythmias. 

Market Dynamics

[124526674]

The increasing prevalence of heart diseases, growing drug development research, and improving reimbursement scenario are all driving the market for cardiovascular drugs. However, adoption of cardiac devices like pacemakers for treatments and the stringent approvals of medications can restrain the growth of global market.

Market Ecosystem

The global cardiovascular drugs market has been analyzed from three perspectives: by drug class, indication, and region. 

Cardiovascular Drugs Market by Drug Class 

[2345732]

The global cardiovascular drugs market based on drug class is divided into anti-hypertensives, anti-coagulants, and anti-hyperlipidemic drugs. The market has been dominated by the anti-coagulants segment. Anti-coagulants reduce the risk of blood clots which can potentially reduce blockage in the arteries. Other drug classes such as anti-hypertensives drugs controls blood pressure by increasing the surface area of blood vessels. The anti - hyperlipidemic drugs lower the cholesterol levels in the body that reduces the risk of heart attacks and strokes. 

Cardiovascular Drugs Market by Indications 

Based on indications, the global cardiovascular drugs market is segmented into hypertension, arrhythmia, coronary artery disease, and hyperlipidemia. Among these, the hypertension or high blood pressure segment has dominated the market. The growth of high blood pressure indication is due to unhealthy diets specifically high consumption of salt, including high caffeine intake, and unhealthy sleep cycle. Arrhythmia is caused when the electrical impulses in the heart does not function properly. The risk factors for this condition include smoking, electrolyte imbalance, and alcohol intake which are observed to be on a phenomenal rise.

Cardiovascular Drugs Market by Region

Based on region, the global cardiovascular drugs market therapy market has been segmented into North America, Europe, Asia Pacific, and the Rest of the World. North America has dominated the global cardiovascular drugs market. Factors contributing to the dominant position of this region are high prevalence of cardiovascular diseases, and presence of major market players in this region. The European market for cardiovascular drug market is characterized by rising cardiovascular disease treatment rates and rising obesity rates throughout the continent. Cardiovascular diseases (CVD) continue to remain the leading cause of mortality in Europe, accounting for 45 percent of all fatalities, according to a WHO report released in 2022. In Europe, the bulk of the more than 4 million annual CVD fatalities are caused by coronary heart disease (CHD) and stroke. The Asia Pacific cardiovascular drugs market is anticipated to grow in the forecast period due to trending alcohol consumption and smoking leading to many cardiac and vascular conditions, increased R&D for drugs and their clinical trials. In addition, according to a report by clinical trials arena in October 2022, over the past ten years, the number of cardiovascular trials has increased by 38% in this Asia Pacific, which is the highest rise in any region, globally. China hosted the greatest number of trials in the region in 2020, accounting for 60.6% of all trials in the area. Similarly, highest proportion of trials are also observed in South Korea 8.4% and India 7.6%. 

Competitive Landscape 

Some of the prominent players operating in the Cardiovascular drug market are 

• Eli Lilly and Company
• Sanofi S.A
• Astra Zeneca Plc.
• Novartis AG
• Boehringer Ingelheim KG
• Johnson & Johnson Services, Inc. 
• Bayer AG
• Abbott Laboratories Inc.
• Roche Holdings Ltd.
• Takeda Pharmaceutical Company

Strategic Developments 

• In February 2022, Cytokinetics reported that the FDA has approved a new drug application omecamtiv mecarbil, for the treatment of heart failure with reduced ejection fraction. 
• In January 2021, the US FDA approved VERQUVO in the United States to lower the risk of cardiovascular death and heart failure hospitalization. In addition, the drug is used for outpatient IV diuretics in adults with symptomatic chronic heart failure and an ejection fraction less than 45%.

Frequently Asked Questions About This Report